论文部分内容阅读
从事于开发血细胞生长因子——如红细胞生长素(EPO)和促粒细胞-巨噬细胞集落刺激因子(GM-CSF)的人从一篇来自新英格兰 Deaconess医院(马萨诸塞州的波士顿)Jerome Groopman’s 艾滋病研究小组的报告中,可以得到坏消息和好消息。令人沮丧的是,艾滋病抗体在体外似乎抑制 EPO 和 GM-CSF 刺激取自艾滋病患者的干细胞产生和分化成为血细胞的能力。这意味着用这些因子以增强艾滋病患者免疫系统免疫力的尝试可能没多大希望。另一方面,许多艾滋病患者缺乏正常的干细胞活性,这样使他们不能服用叠氮胸苷(AZT),因为它能抑制干细胞的活性。令人高兴的是,EPO 和 GM-CSF 确实能在某种程度
People working on the development of hematopoietic growth factors such as erythropoietin (EPO) and granulocyte-macrophage colony stimulating factor (GM-CSF) from a man from Jerome Groopman’s AIDS at Deaconess Hospital in New England (Boston, MA) The research team’s report, you can get bad news and good news. Depressingly, AIDS antibodies appear to inhibit the ability of EPO and GM-CSF to stimulate stem cell production and differentiation into blood cells from AIDS patients in vitro. This means that there may be little hope of using these factors to boost the immune system’s immune system in people with AIDS. On the other hand, many AIDS patients lack normal stem cell activity, thus preventing them from taking AZT because it inhibits stem cell activity. Happily, EPO and GM-CSF do work to some extent